Given the prominent role of Treg cells in promoting immune tolerance within the tumor microenvironment, researchers have developed various therapeutic approaches targeting Treg cells, such as CTLA-4 blockade (84), CD25 modulation (85), and interventions involving receptor superfamilies including tumor necrosis factor receptor (TNFR), immunoglobulin, immune checkpoint receptor, and G protein-coupled receptor (GPCR) superfamily proteins (86, 87). Here, CTLA4 is linked to neoplasm.